Identification of Patients with Acute Myeloblastic Leukemia Who Benefit from the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages 369-377

  Burnett, Alan K ^a   Hills, Robert K ^a   Milligan, Donald ^a   Kjeldsen, Lars ^a   Kell, Jonathan ^a   Russell, Nigel H ^a   Yin, John A L ^a   Hunter, Ann ^a   Goldstone, Anthony H ^a   Wheatley, Keith ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CYTOGENETICS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTOGENETIC ANALYSIS; DENMARK; FEMALE; GREAT BRITAIN; HUMANS; INDIVIDUALIZED MEDICINE; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEW ZEALAND; ODDS RATIO; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952099282     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.4310     Document Type: Article

References (31)

1. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737, 1997 (Pubitemid 27298715)
2. Taussig DC, Pearce DJ, Simpson C, et al: Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106:4086-4092, 2005 (Pubitemid 41775913)
3. Caron PC, Jurcic JG, Scott AM, et al: A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity. Blood 83:1760-1768, 1994 (Pubitemid 24107898)
4. Feldman EJ, Brandwein J, Stone R, et al: Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23:4110-4116, 2005 (Pubitemid 46211316)
5. Larson RA, Boogaerts M, Estey E, et al: Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16:1627-1636, 2002
6. Giles FJ, Kantarjian HM, Kornblau SM, et al: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92:406-413, 2001 (Pubitemid 32664448)
7. Kell WJ, Burnett AK, Chopra R, et al: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102:4277-4283, 2003 (Pubitemid 37494084)
8. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial - The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998
9. Gale RE, Green C, Allen C, et al: The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776-2784, 2008
10. Pallis M, Turzanski J, Harrison G, et al: Use of standardized flow cytometric determinants of multi-drug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. Br J Haematol 104:307-312, 1999 (Pubitemid 29083339)
11. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
12. Burnett AK, Hills RK, Wheatley K, et al: A sensitive risk score for directing treatment in younger patients with AML. Blood 108:10a, 2006 (abstr)
13. Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259, 2009
14. Burnett AK, Hills RK, Milligan DW, et al: Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 28:586-595, 2010
15. Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27: 5397-5403, 2009
16. Büchner T, Berdel WE, Haferlach C, et al: Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27:61-69, 2008
17. Estey E, Döhner H: Acute myeloid leukaemia. Lancet 368:1894-1907, 2006
18. Vellenga E, Griffin JD: The biology of acute myeloblastic leukemia. Semin Oncol 14:365-371, 1987 (Pubitemid 18031391)
19. Walter RB, Gooley TA, van der Velden VH, et al: CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109:4168-4170, 2007 (Pubitemid 46743379)
20. Wadleigh M, Richardson PG, Zahrieh D, et al: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 102:1578-1582, 2003 (Pubitemid 37022544)
21. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005 (Pubitemid 41739007)
22. Schnittger S, Kinkelin U, Schoch C, et al: Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 14:796-804, 2000 (Pubitemid 30235055)
23. Green CL, Koo KK, Hills RK, et al: Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: Impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 28:2739-2747, 2010
24. Virappane P, Gale R, Hills R, et al: Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26:5429-5435, 2008
25. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005 (Pubitemid 40110814)
26. Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006 (Pubitemid 46630738)
27. Care RS, Valk PJ, Goodeve AC, et al: Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121:775-777, 2003 (Pubitemid 36718195)
28. Schnittger S, Kohl TM, Haferlach T, et al: KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107:1791-1799, 2006 (Pubitemid 43289355)
29. Pollard JA, Alonzo TA, Gerbing RB, et al: Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115:2372-2379, 2010
30. Petersdorf S, Kopecky K, Stuart RK, et al: Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. 51st American Society of Hematology Annual Meeting, New Orleans, LA, December 5-8, 2009 (abstr)
31. Borthakur G, Faderl S, Verstovsek S: Molecular response in core binding factor acute myelogenous leukemia with fludarabine, cytarabine, G-CSF and gemtuzumab ozogamicin. Blood 112:676, 2008 (abstr)